Related Experiment Video
Updated: May 8, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Molecular genetics and therapeutic development for GNE myopathy
Wakako Yoshioka1,2, Satoru Noguchi3,4, Ichizo Nishino3,4
1Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan. wyoshioka@ncnp.go.jp.
Genetic diagnostics for GNE myopathy are advancing, enabling detection of complex variants. Accurate genetic testing is crucial for diagnosing GNE myopathy and accessing new therapies.
Area of Science:
- Genetics
- Molecular Biology
- Neurology
Background:
- GNE myopathy is an inherited muscle disorder caused by mutations in the GNE gene.
- The GNE gene is vital for producing sialic acid, essential for cellular functions.
Purpose of the Study:
- To highlight advancements in genetic diagnostics for GNE myopathy.
- To emphasize the link between genetic variants and disease characteristics.
- To underscore the importance of genetic testing for therapeutic access.
Main Methods:
- Review of recent genetic diagnostic techniques, including those for copy number variations and deep intronic variants.
- Analysis of genotype-phenotype correlations in GNE myopathy.
- Assessment of current and emerging therapeutic strategies.
Main Results:
- Advanced genetic testing now identifies a wider range of GNE gene variants, improving diagnostic accuracy.
- Specific GNE genotypes correlate with distinct clinical presentations and disease progression.
- Approved and investigational therapies are becoming available, necessitating precise genetic diagnosis.
Conclusions:
- Comprehensive genetic diagnosis is essential for accurate GNE myopathy identification.
- Understanding complex genetic variants improves patient stratification and treatment.
- Advances in diagnostics and therapies are driving precision medicine for GNE myopathy.
More Related Videos
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
Gene Therapy
Animal Mitochondrial Genetics
Gene Therapy
Satellite Stem Cells and Muscular Dystrophy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Pharmacogenomics: Identification of New Drug Targets